Literature DB >> 26749064

Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium.

Elizabeth R Volkmann1, Yu-Ling Chang1, Nashla Barroso1, Daniel E Furst1, Philip J Clements1, Alan H Gorn1, Bennett E Roth1, Jeffrey L Conklin1, Terri Getzug1, James Borneman2, Dermot P B McGovern3, Maomeng Tong1, Jonathan P Jacobs1, Jonathan Braun1.   

Abstract

OBJECTIVE: To compare colonic microbial composition in systemic sclerosis (SSc) patients and healthy controls and to determine whether certain microbial genera are associated with gastrointestinal (GI) tract symptoms in patients with SSc.
METHODS: Healthy controls were age- and sex-matched (1:1) with adult SSc patients. Cecum and sigmoid mucosal lavage samples were obtained during colonoscopy. The microbiota in these samples were determined by Illumina HiSeq 2000 16S sequencing, and operational taxonomic units were selected. Linear discriminant analysis effect size was used to identify the genera that showed differential expression in SSc patients versus controls. Differential expression analysis for sequence count data was used to identify specific genera associated with GI tract symptoms.
RESULTS: Among 17 patients with SSc (88% female; median age 52.1 years), the mean ± SD total GI Tract 2.0 score was 0.7 ± 0.6. Principal coordinate analysis illustrated significant differences in microbial communities in the cecum and sigmoid regions in SSc patients versus healthy controls (both P = 0.001). Similar to the findings in inflammatory disease states, SSc patients had decreased levels of commensal bacteria, such as Faecalibacterium and Clostridium, and increased levels of pathobiont bacteria, such as Fusobacterium and γ-Proteobacteria, compared with healthy controls. Bifidobacterium and Lactobacillus, which are typically reduced under conditions of inflammation, were also increased in abundance in patients with SSc. In SSc patients with moderate/severe GI tract symptoms, the abundance of Bacteroides fragilis was decreased, and that of Fusobacterium was increased, compared with patients who had no or mild symptoms.
CONCLUSION: This study demonstrates a distinct colonic microbial signature in SSc patients compared with healthy controls. This unique ecologic change may perpetuate immunologic aberrations and contribute to clinical manifestations of SSc.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26749064      PMCID: PMC5561666          DOI: 10.1002/art.39572

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  39 in total

1.  Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host.

Authors:  Jaclyn Strauss; Gilaad G Kaplan; Paul L Beck; Kevin Rioux; Remo Panaccione; Rebekah Devinney; Tarah Lynch; Emma Allen-Vercoe
Journal:  Inflamm Bowel Dis       Date:  2011-01-13       Impact factor: 5.325

2.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis.

Authors:  T Ohkusa; I Okayasu; T Ogihara; K Morita; M Ogawa; N Sato
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Intestinal microbiota in inflammatory bowel disease: friend of foe?

Authors:  Francesca Fava; Silvio Danese
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Bacterial community variation in human body habitats across space and time.

Authors:  Elizabeth K Costello; Christian L Lauber; Micah Hamady; Noah Fierer; Jeffrey I Gordon; Rob Knight
Journal:  Science       Date:  2009-11-05       Impact factor: 47.728

Review 5.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

6.  A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).

Authors:  C G P Roberts; L K Hummers; W J Ravich; F M Wigley; G M Hutchins
Journal:  Gut       Date:  2006-03-09       Impact factor: 23.059

7.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

8.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

9.  Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract.

Authors:  Ayumi Tsuda; Wataru Suda; Hidetoshi Morita; Kageyasu Takanashi; Atsushi Takagi; Yasuhiro Koga; Masahira Hattori
Journal:  Clin Transl Gastroenterol       Date:  2015-06-11       Impact factor: 4.488

10.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.

Authors:  Jose U Scher; Andrew Sczesnak; Randy S Longman; Nicola Segata; Carles Ubeda; Craig Bielski; Tim Rostron; Vincenzo Cerundolo; Eric G Pamer; Steven B Abramson; Curtis Huttenhower; Dan R Littman
Journal:  Elife       Date:  2013-11-05       Impact factor: 8.140

View more
  36 in total

Review 1.  The microbiome in autoimmune diseases.

Authors:  F De Luca; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

Review 2.  Gastrointestinal tract microbiota modifications in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Anna-Maria Hoffmann-Vold
Journal:  Eur J Rheumatol       Date:  2019-12-19

Review 3.  The role of gut microbiota in the pathogenesis of rheumatic diseases.

Authors:  Danli Zhong; Chanyuan Wu; Xiaofeng Zeng; Qian Wang
Journal:  Clin Rheumatol       Date:  2017-09-15       Impact factor: 2.980

4.  Evaluation of risk factors for pseudo-obstruction in systemic sclerosis.

Authors:  Eric Dein; Pei-Lun Kuo; Yun Soo Hong; Laura K Hummers; Christopher A Mecoli; Zsuzsanna H McMahan
Journal:  Semin Arthritis Rheum       Date:  2019-05-23       Impact factor: 5.532

Review 5.  The Microbiome: a Revolution in Treatment for Rheumatic Diseases?

Authors:  James T Rosenbaum; Mark J Asquith
Journal:  Curr Rheumatol Rep       Date:  2016-10       Impact factor: 4.592

Review 6.  The microbiome in autoimmune rheumatic disease.

Authors:  Maximilian F Konig
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-02-07       Impact factor: 4.098

Review 7.  A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.

Authors:  Shannon Teaw; Monique Hinchcliff; Michelle Cheng
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580

8.  Managing gastrointestinal complications in patients with systemic sclerosis.

Authors:  Z H McMahan; D Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-11-13

9.  Gut Microbiota Aberration in Patients of Systemic Sclerosis and Bleomycin-Induced Mice Model.

Authors:  Jungen Tang; Xin Zhou; Xuefen Wu; Shengyan Lin; Bingxia Ming; Jixin Zhong; Baoju Wang; Lingli Dong
Journal:  Front Cell Infect Microbiol       Date:  2021-05-28       Impact factor: 5.293

10.  Association between Appendicitis and Incident Systemic Sclerosis.

Authors:  Kuang-Tsu Yang; James Cheng-Chung Wei; Renin Chang; Chi-Chien Lin; Hsin-Hua Chen
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.